Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxalisib in pediatric DIPG/DMG
NCT03696355Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Nov 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of paxalisib in diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 1 month, Incidence of Adverse Events at 2 years and 1 more. Started Nov 2018; status: completed.
02
Drugs
paxalisib
03
Conditions
diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT03696355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696355.